Bisphosphonate-related osteonecrosis of the jaw and its associated risk factors: A Belgian case series

Laryngoscope

Volumn 119, Issue 2, 2009, Pages 323-329

  Saussez, Sven ^a,d   Javadian, Rokneddine ^b   Hupin, Chloé ^a   Magremanne, Michèle ^c   Chantrain, Gilbert ^a   Loeb, Isabelle ^b   Decaestecker, Christine ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^c ERASME HOSPITAL   (Belgium)

^d UNIVERSITY OF MONS   (Belgium)

Author keywords

Bisphosphonate related osteonecrosis of the jaw; Case series; Risk factor

Indexed keywords

ALENDRONIC ACID; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; CLINDAMYCIN; DOXYCYCLINE; IBANDRONIC ACID; PAMIDRONIC ACID; ZOLEDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; IMIDAZOLE DERIVATIVE;

ADULT; AGED; ARTICLE; BELGIUM; CANDIDA ALBICANS; CLINICAL ARTICLE; CLINICAL FEATURE; CORRELATION ANALYSIS; DATA ANALYSIS; DISSEMINATED CANCER; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERBARIC OXYGEN; JAW OSTEONECROSIS; MALE; MANDIBLE; MAXILLA; MICROBIOLOGY; OSTEOPOROSIS; PRIORITY JOURNAL; PROGNOSIS; RADIOGRAPHY; RETROSPECTIVE STUDY; RISK FACTOR; SYMPTOMATOLOGY; TOOTH EXTRACTION; TREATMENT DURATION; TREATMENT OUTCOME; BONE NECROSIS; CHEMICALLY INDUCED DISORDER; JAW DISEASE; MIDDLE AGED;

ADULT; AGED; AGED, 80 AND OVER; BELGIUM; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; JAW DISEASES; MALE; MIDDLE AGED; OSTEONECROSIS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 63249105860     PISSN: 0023852X     EISSN: None     Source Type: Journal    
DOI: 10.1002/lary.20076     Document Type: Article

References (26)

1. Fleisch H. Bisphosphonates: mechanisms of action and clinical use in osteoporosis-an update. Horm Metab Res 1997; 29:145-150.
2. Berenson JR, Lipton A. Bisphosphonates in the treatment of malignant bone disease. Ann Rev Med 1999; 50: 237-248.
3. Boivin GY, Chavassieux PM, Santora AC, Yates J., Meunier PJ. Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 2000; 27:687-694.
4. Bagger YZ, Tanko LB, Alexandersen P., Ravn P., Christiansen C. Alendronate has a residual effect on bone mass in postmenopausal Danish women up to 7 years after treatment withdrawal. Bone 2003; 33:301-307.
5. Hewitt C., Farah CS. Bisphosphonate-related osteonecrosis of the jaws: a comprehensive review. J Oral Pathol Med 2007; 36:319-328.
6. Marx RE, Sawatari Y., Fortin M., Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005; 63:1567-1575.
7. Hillner BE, Ingle JN, Chlebowski RT, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003; 21:4042-4057.
8. Lacerna L., Hohneker J. Zoledronic acid for the treatment of bone metastases in patients with breast cancer and other solid tumors. Semin Oncol 2003; 30:150-160.
9. Hellstein JW, Marek CL. Bisphosphonate osteochemonecrosis (bis-phossy jaw): is this phossy jaw of the 21st century? J Oral Maxillofac Surg 2005; 63:682-689.
10. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003; 61:1115-1117.
11. Migliorati CA. Bisphosphanates and oral cavity avascular bone necrosis. J Clin Oncol 2003; 21:4253-4254.
12. Pogrel MA. Bisphosphonates and bone necrosis. J Oral Maxillofac Surg 2004; 62:391-392.
13. Cheng A., Mavrokokki A., Carter G., et al. The dental implications of bisphosphonates and bone disease. Aust Dent J 2005; 50:4-13.
14. American Association of Oral and Maxillofacial Surgeons Position Paper on Bisphosphonate-Related Osteonecrosis of the Jaws. J Oral Maxillofac Surg 2007; 65:369-376.
15. Van Poznak C. The phenomenon of osteonecrosis of the jaw in patients with metastatic breast cancer. Cancer Invest 2006; 24:110-112.
16. Wood J., Bonjean K., Ruetz S., et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 2002; 302:1055-1061.
17. Polizzotto MN, Cousins V., Schwarer AP. Bisphosphonateassociated osteonecrosis of the auditory canal. Br J Haematol 2006; 132:114.
18. Durie BG, Katz M., Crowley J. Osteonecrosis of the jaw and biphosphonates. N Engl J Med 2005; 353:99-102.
19. Bamias A., Kastritis E., Bamia C., et al. Osteonecrosis of the jaw in cancer after treatment with biphosphonate: incidence and risk factors. J Clin Oncol 2005; 23:8580-8587.
20. Sambrook P., Cooper C. Osteoporosis. Lancet 2006; 367: 2010-2018.
21. American Dental Association Council on Scientific Affairs. Dental management of patients receiving oral biphosphonates therapy: expert panel recommendations. J Am Dent Assoc 2006; 137:1144-1150.
22. Yarom N., Yahalom R., Shoshani Y., Hamed W., Regev E., Elad S. Osteonecrosis of the jaw induced by orally administrated biphosphonates: incidence, clinical features, predisposing factors and treatment outcome. Osteoporos Int 2007; 18:1363-1370.
23. Ruggiero SL, Mehrortra B., Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with use of biphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004; 62:527-534.
24. Bagan JV, Jimenez Y., Murillo J., et al. Jaw osteonecrosis associated with bisphosphonates: multiple exposed areas and its relationship to teeth extractions. Study of 20 cases. Oral Oncol 2006; 42:327-329.
25. Sasaki A., Nishiyama A., Alcalde RE, et al. Effects of bisphosphonate on experimental jaw metastasis model in nude mice. Oral Oncol 1999; 35:523-529.
26. Danneman C., Gratz KW, Riener MO, Zwahlen RA. Jaw osteonecrosis related to biphosphonate therapy. A severe secondary disorder. Bone 2007; 40:828-834.